Gustave Roussy, Cancer Campus, Grand Paris

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab

Phase 2

Not yet recruiting

Conditions: Cancer

Interventions: Drug: Pembrolizumab and Olaparib
Drug: Pembrolizumab
Drug: Pembrolizumab adjuvant

First Posted Date: 2023-11-03

Last Posted Date: 2024-04-17

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 36

Registration Number: NCT06116578

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

Therapeutic Vaccine in Patients With Human Papillomavirus HPV-positive Oropharyngeal Cancer

Phase 1

Recruiting

Conditions: Head and Neck Carcinoma
Adult Disease

Interventions: Biological: HPVDC injection level dose 1
Biological: HPVDC injection level dose 2
Biological: placebo injection level dose 1
Biological: placebo injection level dose 2

First Posted Date: 2023-08-23

Last Posted Date: 2024-07-29

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 24

Registration Number: NCT06007092

Locations: 🇫🇷
Gustave Roussy, Villejuif, France

Optimization of an Online Stepwise Therapeutic Device Based on a Cognitive-behavioral Approach for Cancer Patients With Insomnia

Not Applicable

Active, not recruiting

Conditions: Insomnia
Cancer

Interventions: Other: Self screening
Other: Phone call
Other: Online questionnaires

First Posted Date: 2023-08-04

Last Posted Date: 2023-08-04

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 322

Registration Number: NCT05977062

Locations: 🇫🇷
Gustave Roussy, Villejuif, France
🇫🇷
Institut de Cancérologie de Montpellier, Montpellier, France
🇫🇷
Centre Léon Bérard, Lyon, France

Preoperative Radiotherapy And ASTX660 in Rectum Cancer

Phase 1

Recruiting

Conditions: Locally-advanced Rectal Cancer

Interventions: Drug: mFOLFIRINOX
Radiation: Pelvic radiotherapy LCRT
Radiation: Pelvic radiotherapy SCRT
Drug: FOLFOX4
Drug: Capecitabine
Drug: TOLINAPANT (ASTX660)
Drug: CAPOX

First Posted Date: 2023-06-22

Last Posted Date: 2024-02-08

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 78

Registration Number: NCT05912075

Locations: 🇫🇷
Centre Léon Bérard, Lyon, Rhöne, France
🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

Engineering Immune Organoids to Study Pediatric Cancer

Not Applicable

Recruiting

Conditions: Brain Tumor
Kidney Tumor
Sarcoma
Neuroblastoma

Interventions: Procedure: Skin biopsy
Procedure: Fresh tumor sample
Biological: Blood sample
Procedure: Healthy tissue from the tumor
Procedure: Spinal cerebrospinal fluid (SCF)

First Posted Date: 2023-06-06

Last Posted Date: 2023-06-06

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 44

Registration Number: NCT05890781

Locations: 🇫🇷
Gustave Roussy, Villejuif, France

Morbidity, Long-term Side Effects and Quality of Life in Germ-cell Tumor Long Survivors Treated with High-dose Chemotherapy and Autologous Stem Cell Transplant

Not Applicable

Recruiting

Conditions: Germ Cell Tumor

First Posted Date: 2023-06-05

Last Posted Date: 2024-10-18

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 180

Registration Number: NCT05889585

Locations: 🇫🇷
Gustave Roussy, Villejuif, France

Thromboprophylaxis in Good and Intermediate Prognosis Advanced Germ Cell Tumors

Phase 3

Recruiting

Conditions: Germ Cell Tumor

Interventions: Drug: Thromboprophylaxis

First Posted Date: 2023-05-24

Last Posted Date: 2024-12-13

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 387

Registration Number: NCT05874063

Locations: 🇫🇷
Hôpital Saint Louis, Paris, France
🇫🇷
CHU de St Etienne, Saint-Étienne, France
🇫🇷
ICO Paul Papin, Angers, France

and more 15 locations

Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma

Phase 1

Recruiting

Conditions: Bone Cancer

Interventions: Drug: regorafenib tablet

First Posted Date: 2023-04-26

Last Posted Date: 2024-11-28

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 24

Registration Number: NCT05830084

Locations: 🇦🇺
Perth Children's Hospital, Perth, Australia
🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇮🇹
Istituto Nazionale dei Tumori, Milan, Italy

and more 3 locations

Validation of a Treatment Algorithm for Poor-Risk NSGCTnon Seminomatous Germ-cell Tumors

Not Applicable

Recruiting

Conditions: Non-Seminomatous Germ Cell Tumor

Interventions: Drug: Dose-dense regimen
Procedure: Early tumor resection or HD-CT
Drug: BEP Protocol

First Posted Date: 2023-01-31

Last Posted Date: 2023-05-18

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 150

Registration Number: NCT05705687

Locations: 🇫🇷
Gustave Roussy, Villejuif, France

Clinical Investigation Evaluating Safety and Efficacy of Selective Intra-arterial 166Holmium Radiation Therapy in Combination With Atezolizumab and Bevacizumab for Non Resectable Hepatocellular Carcinoma

Not Applicable

Active, not recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Device: QuiremSpheres

First Posted Date: 2023-01-31

Last Posted Date: 2024-07-05

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 33

Registration Number: NCT05705791

Locations: 🇫🇷
Gustave Roussy, Villejuif, France
🇫🇷
CHU Nantes, Nantes, France
🇫🇷
AP-HP Hôpital Beaujon, Clichy, France

and more 3 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy